Fig. 1 · Structure

Documents & Downloads

Nimodipine

Cat. No. A10645 CAS 66085-59-4

Calcium Channel inhibitor

Nimodipine is a L-type Ca2+ channel blocker.

In Stock

Publications for Nimodipine

1 publication citing this product

  1. Shiqian Han, .et al. , iScience, 2023, Apr 8;26(5):106613 PMID: 37128603

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Nimodipine inhibits L-type calcium-channel currents in rat cortical neurons. In whole-cell recordings without Bay K8644, the reported IC50 was 24.8 ± 1.3 nM at holding/test potentials of −50/−20 mV, versus 4.8 ± 1.4 µM at −90/0 mV (mean ± SEM; n = 4 cells per condition). Potency therefore depends strongly on the recording conditions. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Calcium channel

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 0.11 μM Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit [PMID: 22761000]
HepG2 EC50 0.39 μM Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation after 16 hrs by luciferase reporter gene assay [PMID: 23688559]
LLC-MK2 IC50 32.31 μM Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay [PMID: 20934347]
LLC-MK2 IC50 96.19 μM Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay [PMID: 20934347]
PC-12 EC50 97.3 μM Neuroprotective activity against glutamate-induced neuronal cell death in rat PC12 cells assessed as increase in cell viability pretreated for 2 hrs followed by glutamate challenge measured after 24 hrs by MTT assay [PMID: 29775304]
SH-SY5Y IC50 14 μM Inhibition of K+-induced voltage gated calcium channel opening in human SH-SY5Y cells assessed as decrease in Ca2+ level after 10 mins by Fluo-4 dye-based fluorescence assay [PMID: 30530190]
Ventricular myocyte IC50 0.3 μM Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes [PMID: 22761000]

Nimodipine Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Nimodipine from 3 published references.

Nimodipine In Vitro Studies

In rat cortical cultures, nimodipine inhibited calcium fluorescence evoked by 300 nM Bay K8644 with a fitted IC50 of 142.4 nM (n = 12 experiments). At 3 µM, it completely blocked the response to 1.1 µM Bay K8644 but only partly blocked the response to 100 mM K+, indicating that this broader depolarization recruits additional calcium-channel components. [1]

In control and NPC1-mutant human fibroblasts, 6 h exposure to nimodipine at 10 or 50 µM reduced processed SREBP2 on immunoblots. A separate 10 µM, 6 h imaging comparison in mutant fibroblasts did not show clear correction of filipin-based cholesterol-storage staining. These cellular results do not establish correction of NPC1 dysfunction or an in vivo benefit of nimodipine. [2]

Inhibition of agonist-evoked calcium flux

Cell-based study · Primary rat cortical cultures, E18 Sprague–Dawley origin; assay development at DIV11–21 [1]

Nimodipine concentration-dependently suppressed Bay K8644-evoked calcium fluorescence. High-potassium responses were only partly blocked, consistent with contributions from other calcium channel types.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of calcium fluorescence evoked by 300 nM Bay K8644 at holding [K+] of 20 mMIC50 142.4 nM; n = 12 experiments[1]
Nimodipine inhibition under two stimulation conditionsqualitative 3 µM partially inhibited 100 mM K+-evoked responses and completely inhibited 1.1 µM Bay K8644-evoked responses[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration–response in Figure 3; 3 µM in Figure 1a control comparison
Exposure duration
Methods specifies 30 min compound incubation at room temperature, at 2× final concentration during incubation; fluorescence recording follows aspiration and agonist addition.
Method
FLIPR calcium fluorescence in primary cortical cultures; peak change from baseline normalized to assay controls
Co-treatment
300 nM Bay K8644 for Figure 3; Figure 1a uses 1.1 µM Bay K8644 or 100 mM K+ in separate conditions. Network activity suppressed with the reported inhibitor cocktail.
Reported limits
Vehicle concentration for these reference-pharmacology curves is not explicitly assigned; DMSO percentages reported for library screening are not borrowed. Figure 3 fitted IC50 has no reported error estimate.
Methods and source locations

Compound reported in the paper: Nimodipine; Compound label in the paper: nimodipine

Compound-level research evidence; no independent validation of a current Adooq lot or enantiomer-specific activity.

Results: Isolation of LTCC-mediated responses; Pharmacology of reference compounds; Figures 1a and 3c–d; Methods: Calcium flux assay, Chemicals, Data analysis

Inhibition of calcium fluorescence evoked by 300 nM Bay K8644 at holding [K+] of 20 mM: Calcium 6 fluorescence; fitted concentration–response. Results identifies IC50; caption calls antagonist fits EC50. No ± is supplied for this fitted value. — Results: Pharmacology of reference compounds; Figure 3c–d and caption

Nimodipine inhibition under two stimulation conditions: Calcium fluorescence; corresponding stimulated controls without nimodipine. No exact inhibition percentage inferred from traces. — Figure 1a, caption and Results: Isolation of LTCC-mediated responses

Voltage-dependent inhibition of neuronal calcium-channel current

Cell-based study · Primary rat cortical neurons, DIV5–14; whole-cell patch clamp with Ba2+ as charge carrier [1]

Nimodipine inhibited neuronal calcium-channel currents with markedly different potency under different holding/test potentials. Selected numeric results exclude the agonist-present curve, whose IC50 differs between narrative and caption.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
No-Bay-K current inhibition at holding/test potentials −50/−20 mVIC50 and maximal inhibition 24.8 ± 1.3 nM; maximal inhibition 96.1 ± 0.8%; n = 4 cells[1]
No-Bay-K current inhibition at holding/test potentials −90/0 mVIC50 and maximal inhibition 4.8 ± 1.4 µM; maximal inhibition 75%; n = 4 cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration–response curves in Figure 5a; fitted IC50 values are endpoints, not treatment concentrations
Exposure duration
Acute perfusion; Methods allows approximately 3 min stabilization in the optimized assay. A separate timing for each no-Bay-K curve is not stated.
Method
Whole-cell voltage clamp at room temperature (~22 °C); Ba2+ current recorded in solutions suppressing sodium and potassium currents
Co-treatment
Selected curves omit Bay K8644; agonist-present curve and peptide-blocker control experiments are separate conditions.
Reported limits
Vehicle percentage and curve-specific exposure times for the selected no-Bay-K protocols are not explicitly specified.
Methods and source locations

Compound reported in the paper: Nimodipine; Compound label in the paper: nimodipine

Compound-level research evidence; no independent validation of a current Adooq lot or enantiomer-specific activity.

Results: Development of a secondary patch clamp assay; Figure 5a,e; Methods: Electrophysiology, Chemicals, Data analysis

No-Bay-K current inhibition at holding/test potentials −50/−20 mV: Whole-cell Ba2+ current; fitted concentration–response; mean ± SEM as specified in Data analysis; compound-free current is control. — Figure 5a caption; Results: Development of a secondary patch clamp assay

No-Bay-K current inhibition at holding/test potentials −90/0 mV: Whole-cell Ba2+ current; mean ± SEM for IC50. Different holding and test potentials; not a single-variable comparison. — Figure 5a caption and Results: Development of a secondary patch clamp assay

SREBP2 processing and cholesterol-storage readouts in fibroblasts

Cell-based study · Human NPC1-mutant GM03123 and control GM05659 fibroblasts; cholesterol-deficient conditions [2]

Nimodipine reduced processed SREBP2 in both fibroblast lines. In NPC1-mutant cells, a separate filipin readout under the same 6 h treatment framework did not show clear correction of cholesterol accumulation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Processed SREBP2 protein in NPC1WT and NPC1mu fibroblastsqualitative immunoblot result Reduced pSREBP2 with 10 and 50 µM nimodipine for 6 h[2]
Filipin/DRAQ5 and LAMP1/DRAQ5 signals in NPC1mu fibroblastsqualitative limiting observation 10 µM nimodipine for 6 h did not show clear normalization of cholesterol-storage staining[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 and 50 µM for Figure 6C immunoblot; 10 µM for Figure 5E–F imaging
Exposure duration
6 h; Figure 6 cultures first maintained in LPDS medium for 24 h
Method
Cell treatment followed by Western blotting or filipin/LAMP1/DRAQ5 imaging in separate readouts
Co-treatment
Selected nimodipine-only conditions; lithium comparators are separate. Western method includes ALLN before harvest.
Reported limits
Nimodipine vehicle, lot/purity and replication for Figure 6C/5E–F not specified in the relevant captions/methods. SI S4 not retrieved, so the 1 µM claim is not adopted.
Methods and source locations

Compound reported in the paper: Nimodipine; Compound label in the paper: Nimo

Compound-level research evidence; no independent validation of a current Adooq lot or enantiomer-specific activity.

Results: Lithium decreases processed SREBP2 by damping the intracellular Ca2+ level; Figure 6C; Figure 5E–F; STAR Methods: Key resources table, Cells, Western blotting, Filipin/LAMP1/DRAQ5 staining

Processed SREBP2 protein in NPC1WT and NPC1mu fibroblasts: Western blot versus 0 µM control, β-actin loading control; full-length SREBP2 also shown. No exact fold reduction inferred; replicate number for this panel not specified in caption. — Figure 6C image/caption and associated Results

Filipin/DRAQ5 and LAMP1/DRAQ5 signals in NPC1mu fibroblasts: Filipin and LAMP1 imaging with control/Mock comparator; DRAQ5 normalization in Figure 5F. No exact magnitude or statistical equivalence inferred. — Figure 5E–F image/caption

Nimodipine In Vivo Studies

In female SJL/J mice with EAE, nimodipine at 10 mg/kg by daily subcutaneous injection, starting on day 23, was associated with lower clinical scores than vehicle in typical and atypical disease cohorts. Balance-deficit scores were also lower in a subset. Groups were matched by disease severity, with the more affected group preferentially assigned nimodipine when unequal; this allocation and selective inclusion limit interpretation. [3]

Clinical disease scores in a mouse EAE model

Animal study · Female SJL/J mice, 8 weeks at model induction; typical and atypical EAE cohorts [3]

Nimodipine-treated mice had lower clinical EAE scores than vehicle-treated mice in both phenotypes. The study also reported lower balance-deficit scores in a subset. Nonrandom allocation and selected inclusion limit causal interpretation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Clinical EAE scores and balance-deficit scoredirection and group sizes Lower clinical scores: typical EAE, nimodipine n = 32 vs vehicle n = 24; atypical EAE, n = 18 vs n = 22. Balance subset, n = 10 vs n = 11.[3]

Conditions shared by the study groups

Route
Subcutaneous injection
Frequency
Daily
Treatment course
Starting day 23 after model induction; 19–37 consecutive days as reported in main Results
Vehicle
5% ethanol, 5% DMSO, 40% PEG 400, 50% PBS (Results); Methods lists PBS as remainder.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Nimodipine versus vehicle in EAE
10 mg/kg body weight
Vehicle only; typical n = 24, atypical n = 22; balance subset n = 11Lower clinical scores in typical (treated n = 32) and atypical (treated n = 18) cohorts; lower balance-deficit scores in subset (treated n = 10).[3]
Nimodipine versus vehicle in EAE
Model: Female SJL/J mice, 8 weeks at model induction; typical and atypical EAE cohorts
Reported limits: Not a randomized comparison; groups matched for pretreatment score and more affected group preferentially assigned nimodipine if unequal. Only mice with comparable courses across vendors were included.
Methods and source locations

Compound reported in the paper: Nimodipine; Compound label in the paper: nimodipine

Compound-level research evidence; no independent validation of a current Adooq lot or enantiomer-specific activity.

Results: Nimodipine Treatment Significantly Attenuated the Clinical Course of EAE; Figure 1A–C; Materials and Methods: Mice, treatment/allocation and score definitions; Statistics

Clinical EAE scores and balance-deficit score: Daily clinical scoring; balance test for sensorimotor deficits. Figure 1 uses Mann–Whitney tests (*P ≤ 0.05; ***P ≤ 0.001 legend thresholds); graphs show means ± SEM per Statistics. No exact plotted score or percentage extracted. — Figure 1A–C image/caption; first Results subsection

Nimodipine versus vehicle in EAE · Figure 1A–C; first Results subsection; Materials and Methods: treatment/allocation

Specifications

Manufacturer Adooq Bioscience
Actions Blocker
CAS Number 66085-59-4
Applications Calcium Channel inhibitor
Formula C21H26N2O7
Molecular Weight 418.45
SMILES
CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 82 mg/mL (195.96 mM)
Water Insoluble
Ethanol 82 mg/mL (195.96 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Nimodipine Research References

  1. [1] Hagan R, Rex E, Woody D, et al. Development of phenotypic assays for identifying novel blockers of L-type calcium channels in neurons Scientific reports (2021). PMID: 33432098 DOI: 10.1038/s41598-020-80692-5 Source material
  2. [2] Han S, Wang Q, Song Y, et al. Lithium ameliorates Niemann-Pick C1 disease phenotypes by impeding STING/SREBP2 activation iScience (2023). PMID: 37128603 DOI: 10.1016/j.isci.2023.106613 Source material
  3. [3] Schampel A, Volovitch O, Koeniger T, et al. Nimodipine fosters remyelination in a mouse model of multiple sclerosis and induces microglia-specific apoptosis Proceedings of the National Academy of Sciences of the United States of America (2017). PMID: 28381594 DOI: 10.1073/pnas.1620052114 Source material

Publications

1 publication citing this product

  1. Shiqian Han, .et al. , iScience, 2023, Apr 8;26(5):106613 PMID: 37128603

Added to your cart

View Cart Checkout
Loading...